Clinical trial · Interventional
PTC in Personalizing Neoadjuvant Therapy for Patients With Advanced Gastrointestinal Tumor
Patient-derived Tumor-like Cell Clusters (PTC) in Personalizing Neoadjuvant Therapy for Patients With Advanced Gastrointestinal Tumor: A Prospective, Open-label and Randomized Study
NCT05280210CI-TRIAL-00057128unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the value of PTC drug screening technique in selecting neoadjuvant therapy for advanced gastrointestinal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Neoplasms | Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PTC drug screening | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Neoadjuvant therapy based on PTC drug screening
- description
- Patients will receive neoadjuvant therapy based on PTC drug screening. The regimen is complied with NCCN and CSCO guidelines. PD-1 inhibitor will be used if effective in drug screening.
- interventionNames
- Other: PTC drug screening
- type
- NO_INTERVENTION
- label
- Neoadjuvant therapy based on clinical experience
- description
- Patients will receive neoadjuvant therapy based on clinical experience. The regimen is complied with NCCN and CSCO guidelines.
Primary outcomes (1)
- measure
- pathological complete response rate(pCR)
- timeFrame
- immediately evaluated after surgery
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosed of gastrointestinal adenocarcinoma by biopsy * existence of initially resectable lesions evaluated by investigators * indications of neoadjuvant chemotherapy including: 1) locally advanced gastric cancer cT1-2N1-3M0 \& cT3-4N0-3M0; 2) locally advanced colorectal cancer cT3-4 or N+; 3)colorectal carcinoma with synchronous liver metastases: CRS≤2; 4)other patients who are considered to be appropriate to receive neoadjuvant chemotherapy determined by MDT * never receive any tumor related treatment including chemotherapy, radiotherapy, and immune therapy * never diagnosed of other malignancies * able to tolerate chemotherapy * ECOG≤2 * life expectance \>6 months * at least 1 measurable lesions(according to RECIST 1.1) * informed consent Exclusion Criteria: * pregnant or lactating women * participating in other clinical trials within 6 months * MSI-H or dMMR or EBER(+) * lesion located within 10cm from anal margin * severe liver dysfunction * severe renal dysfunction * cognitive disorder, mental disease or poor compliance * allergic to known chemotherapeutic agents * other conditions not suitable to participate in this trial determined by investigators
References
Publications (0)
Data not yet available
No reference posted for this study.